TY - JOUR
T1 - Effects of pentoxifylline on inflammatory markers and blood pressure
T2 - a systematic review and meta-analysis of randomized controlled trials
AU - Brie, Daniel
AU - Sahebkar, Amirhossein
AU - Penson, Peter E
AU - Dinca, Madalina
AU - Ursoniu, Sorin
AU - Serban, Maria-Corina
AU - Zanchetti, Alberto
AU - Howard, George
AU - Ahmed, Ali
AU - Aronow, Wilbert S
AU - Muntner, Paul
AU - Lip, Gregory Y H
AU - Wong, Nathan D
AU - Rysz, Jacek
AU - Banach, Maciej
AU - Lipid, Blood Pressure Meta-analysis Collaboration (LBPMC) Group
PY - 2016
Y1 - 2016
N2 - INTRODUCTION: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits.AIM: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials.METHODS: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics.RESULTS: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P < 0.001, 11 treatment arms) and CRP (WDF: -1.39 mg/l, 95% CI: -2.68, -0.10; P = 0.034, five treatment arms). No alteration in plasma IL-6 concentration was observed. The impact of pentoxifylline on plasma TNF-α levels was found to be positively associated with treatment duration (slope: 0.031; 95% CI: 0.004, 0.057; P = 0.023) but independent of pentoxifylline dose (slope: -0.0003; 95% CI: -0.002, 0.001; P = 0.687).CONCLUSION: Pentoxifylline did not alter BP or plasma IL-6 concentration, but significantly reduced circulating TNF-α and CRP concentrations.
AB - INTRODUCTION: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits.AIM: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials.METHODS: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics.RESULTS: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P < 0.001, 11 treatment arms) and CRP (WDF: -1.39 mg/l, 95% CI: -2.68, -0.10; P = 0.034, five treatment arms). No alteration in plasma IL-6 concentration was observed. The impact of pentoxifylline on plasma TNF-α levels was found to be positively associated with treatment duration (slope: 0.031; 95% CI: 0.004, 0.057; P = 0.023) but independent of pentoxifylline dose (slope: -0.0003; 95% CI: -0.002, 0.001; P = 0.687).CONCLUSION: Pentoxifylline did not alter BP or plasma IL-6 concentration, but significantly reduced circulating TNF-α and CRP concentrations.
U2 - 10.1097/HJH.0000000000001086
DO - 10.1097/HJH.0000000000001086
M3 - Review article
C2 - 27512972
SN - 0263-6352
VL - 34
SP - 2318
EP - 2329
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 12
ER -